# Granata Bio

> Granata Bio is a Boston-based biopharmaceutical company building a portfolio of fertility and reproductive-health therapies. Founded in 2018, it in-licenses and develops medications used in IVF outside the US, runs its own clinical programs, and is expanding into ovarian biology. Its lead asset is an investigational human menopausal gonadotropin in the pivotal Phase III GRACE study, and its 2025 acquisition of Oviva Therapeutics added a first-in-class therapeutic aimed at extending ovarian function. The company targets the multi-billion-dollar global infertility medication market with the goal of expanding patient access and improving IVF outcomes.

- **Founded:** 2018
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Evan Sussman (Co-Founder & CEO), Sarah Faranda (Co-Founder), David Paller (Co-Founder), Marc Chung (Co-Founder (Clinical & Regulatory))
- **Team size:** ~17 employees
- **Products:** Investigational Human Menopausal Gonadotropin (GRACE study), Next-generation hypoglycosylated FSH, OVI-586 (via Oviva Therapeutics), IVF in-licensed portfolio
- **Notable:** Raised more than $43M in total funding across Seed, Series A, and Series A+ rounds., Series A led by GV (Google Ventures) in January 2024., Acquired Oviva Therapeutics in April 2025 to add a first-in-class ovarian-function asset.

## Products & services

- **Investigational Human Menopausal Gonadotropin (GRACE study)** — Lead asset in the pivotal Phase III GRACE study, evaluating multiple-follicle development, pregnancy, and cumulative live birth in assisted reproductive technology (IVF) cycles. Study began November 2025 with primary completion estimated November 2028.
- **Next-generation hypoglycosylated FSH** — A novel recombinant follicle-stimulating hormone being developed through a joint venture with Georgetown Equity Partners, advancing toward first-in-human studies.
- **OVI-586 (via Oviva Therapeutics)** — First-in-class therapeutic designed to extend ovarian function and enhance female health span, with potential applications in IVF, menopause, and contraception. Built on IP licensed from Massachusetts General Hospital.
- **IVF in-licensed portfolio** — Strategic medications used in IVF outside the US, in-licensed for clinical development and commercialization in North America, spanning four IVF product classes including ovarian stimulation and luteal phase support.

## Achievements

- Raised more than $43M in total funding across Seed, Series A, and Series A+ rounds.
- Series A led by GV (Google Ventures) in January 2024.
- Acquired Oviva Therapeutics in April 2025 to add a first-in-class ovarian-function asset.
- Advanced its lead gonadotropin into the pivotal Phase III GRACE study, enrolling across US fertility centers.
- Formed a joint venture with Georgetown Equity Partners to develop next-generation FSH.
- Assembled a pipeline spanning four IVF product classes.

## Latest updates

- **2025-11** — Reported strong enrollment momentum in the pivotal Phase III GRACE study of its investigational gonadotropin; study began November 2025 with primary completion estimated November 2028.
- **2025-04** — Acquired US-based Oviva Therapeutics, adding lead candidate OVI-586 and an ovarian-aging focus to its women's-health portfolio.
- **2025-01** — Raised $15M Series A+ from existing investors led by Gedeon Richter and CooperSurgical to expand the reproductive-health pipeline.
- **2024-01** — Raised $14M Series A led by GV to accelerate its fertility biopharma pipeline.

## Links

- Website: https://granata.bio
- LinkedIn: https://www.linkedin.com/company/granatabio
- Twitter/X: https://twitter.com/Granata_Bio

---

Profile page: https://yespress.io/granata-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-15